Biocodex, a long-standing player in microbiota research, has made a significant investment in MRM Health, a Belgian clinical-stage biotechnology company. The French pharmaceutical company is leading a €55 million Series B funding round for MRM Health, contributing €11 million initially with the potential for a total investment reaching approximately €30 million.
This substantial investment demonstrates Biocodex‘s confidence in MRM Health‘s technology and its potential to revolutionize the treatment of inflammatory diseases. The funding round also included participation from several other investors, including ATHOS, BNP Paribas Fortis Private Equity, SFPIM (Belgium‘s sovereign wealth fund), Ackermans & van Haaren (AvH), OMX Ventures Europe (OMX), and Qbic II.
MRM Health is focused on developing innovative live biotherapeutic products (LBPs) targeting chronic inflammatory diseases. The company’s lead product, MH002, has shown promising results in clinical trials for ulcerative colitis and pouchitis. MRM Health‘s proprietary CORAL® technology platform uses artificial intelligence to design, optimize, and manufacture live microbial consortia, ensuring high reproducibility and tolerability.
Biocodex‘s CEO, Nicolas Coudurier, highlighted the strategic alignment between the two companies, emphasizing the combination of Biocodex‘s extensive experience in microbiota research with MRM Health‘s cutting-edge LBP technology. This collaboration aims to provide effective solutions for patients suffering from various inflammatory conditions.
Sam Possemiers, CEO of MRM Health, expressed his satisfaction with securing Biocodex as a lead investor and strategic partner. He emphasized that the investment validates the potential of the CORAL® platform and strengthens the company’s ability to develop and scale its microbiome-based therapeutics.
Biocodex, operating in over 100 countries, is known for its work in microbiota research, women’s health, rare diseases, and common health conditions. MRM Health, meanwhile, is dedicated to addressing unmet medical needs in chronic inflammatory diseases through its innovative approach to microbiome-based therapies. The partnership positions both companies for future growth in the rapidly expanding field of microbiome therapeutics.
Related
